GCA Altium advises in regard to the sale of the majority of the Sartorius joint heirship to Karin Sartorius-Herbst and a consortium led by Armira
The Sartorius Group, founded in 1870 and headquartered in Germany, is an international pharmaceutical and laboratory equipment supplier with a market cap of c. EUR 35bn.
With its innovative products and services, Sartorius enables pharmaceutical researchers and lab personnel to simplify workflows, minimise human errors and speed up their work. The firm provides solutions that shorten the lengthy and difficult search for active ingredients, including new methods for cell analysis to unlock the great potential of new therapeutic approaches, and software converting data into safe, actionable insights.
Sartorius also provides the essential products, technologies and expertise to produce biopharmaceuticals reliably and efficiently. In fact, the firm has been pioneering and setting the standards for single-use products that are currently used throughout all biopharmaceutical manufacturing processes.
The company has been annually growing by double digits on average and regularly expanding its portfolio through acquisitions of complementary technologies. In the fiscal year 2020, Sartorius earned sales revenue of some EUR 2.34 billion. At the end of 2020, the firm employed nearly 11,000 people at approximately 60 manufacturing and sales sites, serving customers around the globe.
Karin Sartorius-Herbst has been a member of the Sartorius joint heirship since it was established in 1998. Armira is leading a consortium of long-term oriented entrepreneurs and entrepreneurial families.
The agreement is subject to the usual approvals and is expected to close by the end of 2021. The parties involved have agreed not to disclose any further details of the transaction.